Allterum’s Antibody

Allterum is building a franchise addressing the IL-7R pathway starting with 4A10, a monoclonal antibody targeted against CD127. CD127 is part of a receptor complex located on T-cells and Pre B-cells. Especially in the context of cancer cells, CD127 plays a critical role in driving cancer growth, being frequently expressed at a higher level, or in a more activated form, and has been posited as playing a key role in ALL oncogenesis and chemotherapy-resistance. Allterum’s 4A10 antibody is the first immunotherapy approach to target CD127. 4A10 uses the patient’s own immune system to target cancer cells for destruction. 4A10 is currently in development for the treatment of relapsed leukemia and will expand to other heme malignancies and solid tumors.

4A10 and CD127 (also known as IL-7Rα) in Scientific Literature

Review highlighting oncogenic mutations in the IL-7 pathway

IL-7R is highlighted for its potential oncogenic effects in T-cell ALL

IL-7R signaling can drive leukemia development, acceleration, and resistance to chemotherapy

Targeting IL-7R with an antibody-drug conjugate is efficacious in models of T-cell ALL

IL-7R may play a key role in driving Ph-like and Ph+ B-cell acute lymphoblastic leukemia

Glucocorticoid resistance is reversible with targeted inhibition of the IL-7 pathway

CD127 is a promising target for the treatment of pediatric acute lymphoblastic leukemia


Advancing an innovative solution for a critical and unmet medical need